Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities
Clinical and Translational Oncology · 10.06.2026
DOI: 10.1007/s12094-026-04451-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, online erschienen am 10.06.2026. Verfasst von Farida Khamidova und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathological Anatomy, Samarkand State Medical University, Samarkand, Uzbekistan. Xamidovaf.m.05@mail.ru. Die Arbeit nennt 109 Literaturangaben.
Abstract (Originalsprache)
Trogocytosis has emerged as a critical regulator of tumor immunity and cancer immunotherapy. This contact-dependent process enables the transfer of membrane fragments and associated molecules between interacting cells, thereby reshaping cellular phenotype, signaling, and immune function within the tumor microenvironment (TME). Recent evidence demonstrates that trogocytosis exerts context-dependent effects in cancer, functioning as both a mechanism of antitumor immunity and a driver of immune evasion and therapeutic resistance. Immune cells can utilize trogocytosis to mediate tumor cell killing through trogoptosis, enhance antigen presentation, and promote immune priming. Conversely, malignant cells exploit this process to acquire immunosuppressive molecules, downregulate tumor-associated antigens, induce exhaustion and fratricide of effector lymphocytes, and establish an immunosuppressive niche that favors tumor progression. In this review, we comprehensively discuss the mechanistic basis of trogocytosis in innate and adaptive immune responses against cancer and highlight its role in tumor progression, immune escape, and modulation of the TME. We further examine the implications of trogocytosis in cellular immunotherapies, particularly chimeric antigen receptor (CAR)-engineered immune cells and dendritic cell (DC) vaccination. Finally, we summarize emerging therapeutic strategies aimed at modulating trogocytosis to improve the efficacy and durability of cancer immunotherapies. A deeper understanding of trogocytosis and its context-specific functions may support the development of safer and more effective next-generation immunotherapeutic approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathological Anatomy, Samarkand State Medical University, Samarkand, Uzbekistan. Xamidovaf.m.05@mail.ru.
- Tashkent State Pedagogical University, Tashkent, Uzbekistan.
- Department of General Surgery, Tashkent State Medical University, Tashkent, Uzbekistan.
- Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Uzbekistan.
- Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia.
- Department of Pedagogy, University of Economics and pedagogy, Karshi, Uzbekistan.
Zitieren
APA
Khamidova, F., Babaeva, Z., Jafarov, K., Kasimova, M., Yumashev, A., Doniyorova, D., Norqobilova, R., Raxmatullayev, J., & Sardor, K. (2026). Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04451-0
Vancouver
Khamidova F, Babaeva Z, Jafarov K, Kasimova M, Yumashev A, Doniyorova D, et al. Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04451-0
BibTeX
@article{Khamidova2026,
author = {Khamidova, Farida and Babaeva, Zarina and Jafarov, Khasan and Kasimova, Mukhlisakhon and Yumashev, Alexey and Doniyorova, Dildora and Norqobilova, Raykhona and Raxmatullayev, Jurabek and Sardor, Khazratkulov},
title = {Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities},
journal = {Clinical and Translational Oncology},
year = {2026},
doi = {10.1007/s12094-026-04451-0}
}
EUVIMED